Haoxi Health Technology Limited
Haoxi Health Technology Limited Fundamental Analysis
Haoxi Health Technology Limited (HAO) shows strong financial fundamentals with a PE ratio of 0.82, profit margin of 11.82%, and ROE of 21.47%. The company generates $0.1B in annual revenue with strong year-over-year growth of 71.88%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 76.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze HAO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentHAO demonstrates superior asset utilization.
Valuation Score
ExcellentHAO trades at attractive valuation levels.
Growth Score
ExcellentHAO delivers strong and consistent growth momentum.
Financial Health Score
ExcellentHAO maintains a strong and stable balance sheet.
Profitability Score
WeakHAO struggles to sustain strong margins.
Key Financial Metrics
Is HAO Expensive or Cheap?
P/E Ratio
HAO trades at 0.82 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, HAO's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Haoxi Health Technology Limited at 0.18 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.52 times EBITDA. This is generally considered low.
How Well Does HAO Make Money?
Net Profit Margin
For every $100 in sales, Haoxi Health Technology Limited keeps $11.82 as profit after all expenses.
Operating Margin
Core operations generate -6.10 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $21.47 in profit for every $100 of shareholder equity.
ROA
Haoxi Health Technology Limited generates $17.95 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Haoxi Health Technology Limited generates limited operating cash flow of $-8.70M, signaling weaker underlying cash strength.
Free Cash Flow
Haoxi Health Technology Limited generates weak or negative free cash flow of $-8.70M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.16 in free cash annually.
FCF Yield
HAO converts -41.06% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.82
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.18
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.25
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.11
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.05
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.21
vs 25 benchmark
ROA
Return on assets percentage
0.18
vs 25 benchmark
ROCE
Return on capital employed
-0.11
vs 25 benchmark
How HAO Stacks Against Its Sector Peers
| Metric | HAO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.82 | 21.66 | Better (Cheaper) |
| ROE | 21.47% | 1190.00% | Weak |
| Net Margin | 11.82% | -55754.00% (disorted) | Strong |
| Debt/Equity | 0.11 | 1.32 | Strong (Low Leverage) |
| Current Ratio | 5.05 | 1.59 | Strong Liquidity |
| ROA | 17.95% | -202359.00% (disorted) | Strong |
HAO outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Haoxi Health Technology Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
208.54%
Industry Style: Growth, Technology, Streaming
High GrowthEPS CAGR
247.06%
Industry Style: Growth, Technology, Streaming
High GrowthFCF CAGR
-123.06%
Industry Style: Growth, Technology, Streaming
Declining